The CmeABC efflux pump in Campylobacter jejuni confers resistance to structurally divergent antimicrobials, and inhibition of CmeABC represents a promising strategy to control antibiotic-resistant Campylobacter. Antisense peptide nucleic acids (PNAs) targeting the three components of CmeABC were evaluated for inhibition of CmeABC expression. The result revealed a synergistic effect of the PNAs targeting CmeA and CmeB on sensitizing C. jejuni to antibiotics. This finding further demonstrates the feasibility of using PNAs to potentiate antibiotics against antibiotic-resistant Campylobacter.
C
ampylobacter jejuni is a major food-borne pathogen accounting for 400 to 500 million cases of diarrhea each year worldwide (1) . This organism is increasingly resistant to clinically important antibiotics, particularly fluoroquinolone (FQ) antimicrobials (2) . The CmeABC efflux pump in Campylobacter confers resistance to a broad range of antimicrobials and toxic compounds (3) . In addition, this efflux pump functions synergistically with other mechanisms (e.g., spontaneous mutations in antibiotic targets) in mediating high-level resistance to antibiotics (3) . Cme-ABC is also important for bile resistance and is essential for Campylobacter colonization in the intestinal tract of animal hosts (4) .
Due to the significant role of CmeABC in antibiotic resistance, inhibition of CmeABC represents a promising strategy to control antibiotic-resistant Campylobacter. Efflux pump inhibitors, such as phenyl-arginine-␤-naphthylamide (PA␤N), have been evaluated to inhibit antibiotic efflux in Campylobacter (5). The general findings are that PA␤N has a significant impact on erythromycin (Ery) but has limited or no effect on the MICs of FQ antimicrobials in Campylobacter (5-7). Peptide nucleic acids (PNAs) are synthetic homologs of nucleic acids in which the phosphate backbone of polynucleotides is replaced by a flexible pseudopeptide polymer (8) . PNAs function as antisense agents by binding specifically to complementary sequences in DNA and RNA and inhibiting gene expression and/or translation (9) . Recently, we showed that a CmeA-specific PNA reduced the expression of CmeA and increase the susceptibility of C. jejuni strains resistant to both ciprofloxacin (Cipro) and erythromycin (Ery) (10) . However, it remains unknown if PNAs against other components of CmeABC are also effective in inhibiting the function of the efflux pump and if combinatorial use of PNAs against different components of the efflux system enhances the inhibitory effect.
In this study, we designed multiple PNAs against all three components of the CmeABC efflux pump based on the genome sequence of C. jejuni NCTC 11168 and evaluated their activities individually and in combination using a wild-type strain (NCTC 11168), a Cipro-resistant mutant (62301R33), and an Ery-resistant mutant (JL272). The CmeA-specific PNA sequence is TCAT GGTTTTGC, the CmeB-specific PNA sequence is ATTATTGTG CTC, and the CmeC-specific PNA sequences are CATGAACCT TAC, CCTTACCTCTTT, and TATTCATGAACC. A negativecontrol PNA (ACACACACACAC) was also synthesized. All PNAs were conjugated to the oligopeptide KFFKFFKFFK to improve PNA entry into bacterial cells (11) .
The PNAs were added to Campylobacter cultures in MuellerHinton (MH) broth at different concentrations (0, 1, 2, and 4 M). To detect if the PNAs inhibited CmeABC expression, SDS-PAGE and Western blotting were performed with antibodies against CmeA, CmeB, and CmeC as described previously (10) . Addition of the CmeA PNA to culture media reduced the expression of CmeA, as well as that of CmeB and CmeC (Fig. 1A) . The CmeB PNA reduced the expression of CmeB, but it did not affect the expression of CmeC and CmeA (Fig. 1A) . Unlike the CmeA and CmeB PNAs, none of the three CmeC PNAs examined in this study altered the expression of CmeC as determined by Western blotting (partly shown in Fig. 1A) . Combination of the CmeA and CmeB PNAs reduced the expression of all three proteins of the efflux pump. Compared with the individual PNAs, the combination of CmeA and CmeB PNAs produced stronger inhibition of CmeABC expression (Fig. 1A) . Densitometric analysis of the blotting results also confirmed the synergistic effect of the PNA combination on the expression of CmeABC (Fig. 1B) . The negativecontrol PNA did not affect the expression of CmeABC (data not shown). None of the examined PNAs affected the expression of the major outer membrane protein (MOMP), which was used as an internal control (Fig. 1A) .
It should be pointed out that CmeC is an N-glycosylated protein and shows as two bands, resulting from different glycosylated forms (3) . The finding that the tested CmeC PNAs had no effect on the translation of CmeC was surprising, and the exact reason for this observation is unknown. One possibility is that the CmeC mRNA has unique secondary structures that prevent the binding of PNAs. Alternatively, the ribosome binding site (RBS) of CmeC is embedded in the coding sequence of CmeB, and the translation from CmeB might alleviate the inhibition of CmeC by PNAs.
To assess whether the PNAs against CmeA, CmeB, and CmeC affected the susceptibility of C. jejuni to antimicrobials, we measured the MICs of Cipro and Ery in the presence of the PNAs either individually or in combination using a microtiter broth dilution method described previously (10) . The key results are shown in Table 1 . At 1 and 2 M, none of the PNAs altered the susceptibility of NCTC 11168 to Cipro and Ery. At 4 M, the CmeA-specific PNA and the CmeB-specific PNA increased the susceptibility of NCTC 11168 to Cipro and Ery by 2-fold, but the CmeC PNAs did not show any effects, consistent with the results from Western blotting. Notably, the combination of the two PNAs against CmeA and CmeB at 1 M each resulted in 16-and 4-fold decreases in the MICs of Cipro and Ery, respectively, in NCTC 11168 (Table 1) . At higher concentrations (2 and 4 M), this combination further sensitized NCTC 11168 to the antibiotics (Table 1) . We also evaluated the PNAs in a Cipro-resistant strain (62301R33) and an Ery-resistant strain (JL272). Isolate 62301R33 has the C257T mutation in gyrA, which contributes to the highlevel resistance to Cipro (12) , while JL272 has the A2074G mutation in 23S rRNA, mediating high resistance to erythromycin (12, 13) . In both cases, the target mutations work synergistically with CmeABC in conferring high-level resistance to the antibiotics. In 62301R33, the PNAs against CmeA and CmeB reduced the Cipro MIC 8-and 2-fold, respectively, while the combination of the two resulted in 16-fold reduction in the MIC. In JL272, the two PNAs each produced a 2-fold reduction in Ery MIC and combination of the two reduced the MIC by 4-fold.
These results indicate that CmeABC PNAs potentiate the activities of antibiotics in both wild-type and antibiotic-resistant strains of C. jejuni. The results also suggest that the inhibition of CmeABC expression and function depends on the target gene, with CmeA and CmeB PNAs showing the highest efficiency. Importantly, this study demonstrates a synergistic effect of the PNAs against CmeA and CmeB in sensitizing C. jejuni to antibiotic when used in combination. These findings further illustrate the feasibility of using PNAs to potentiate antibiotics against antibiotic-resistant Campylobacter. Considering that PNAs are resistant to proteases and nucleases and are stable in acidic pH (12, 14) , antiCmeABC PNAs may be potentially used as an adjunctive therapy for antibiotic-resistant Campylobacter in vivo. 
